Qiagen Launches CE-marked Version of QuantiFERON SARS-CoV-2 to Assess T-cell Response to COVID-19
By LabMedica International staff writers Posted on 03 Dec 2021 |
QIAGEN N.V. (Venlo, Netherlands) has obtained the CE marking for its QuantiFERON SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.
COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. T-cell response to SARS-CoV-2 declines much more slowly than antibody response and may indicate how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those are who have recovered many months – possibly even years – after having been infected. Serology tests, which measure the antibodies, often generate positive test results after vaccination but are unable to assess cellular responses.
The QuantiFERON SARS-CoV-2 assay detects CD4+ and CD8+ T-cell responses, thereby enabling a much more comprehensive assessment of immunity generated by COVID-19 vaccines. The assay is based on QIAGEN’s QuantiFERON interferon gamma release technology, which is globally recognized as an easy-to-use T-cell assay that employs whole blood and – unlike other T-cell assays – does not require the purification of lymphocytes for T-cell measurement.
“T-cells provide valuable insights into our immune system’s response to COVID-19,” said Jean-Pascal Viola, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us,” he said. “We are excited about our QuantiFERON technology enabling the assessment of immune responses that are crucial for the prevention and management of the disease.”
Related Links:
QIAGEN N.V.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants